-
FDA rejects the application of new epilepsy drugs from Weicai
Time of Update: 2011-08-01
Source: China Council for the promotion of drugs, August 1, 2011, according to the report of FierceBiotech, FDA has refused to accept the new drug application (NDA) of perampanel, which was submitted
-
Neuroscientists at City University of Hong Kong have discovered a new drug candidate to treat epilepsy
Time of Update: 2023-01-05
A research team co-led by neuroscientists at the City University of Hong Kong (CityU) recently discovered and developed a new drug candidate that has the potential to effectively treat TLE by inhibiting neuroinflammation.
-
"Cool down" the brain! Science has brought a new dawn to epilepsy gene therapy, which is more effective than drugs
Time of Update: 2022-12-04
A recent study in Science made a major breakthrough in addressing this problem, and co-corresponding author Dr. Gabriele Lignani said: "We have developed gene therapies that can precisely target abnormally active neurons and restore their activity to normal.
-
NEUROBIOL DIS A new generation of KCNQ2-channel antiepileptic drugs targeted for the treatment
Time of Update: 2022-10-03
On September 14, 2022, the Gao Zhaobing Research Group of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Professor Maurizio Taglialatela of Federico II University in Naple
-
The field of express epilepsy is approved again, and the prospect of fenfluramine "old drug new" is promising
Time of Update: 2022-04-28
S. Food and Drug Administration (FDA) has approved the expanded indication of Fintepla (fenfluramine) for the treatment of patients two years of age and older with Lennox- Seizures associated with Gastaut syndrome (LGS) .
-
new nano-drug delivery system, on-demand drug delivery system is expected to improve the effect of epilepsy treatment
Time of Update: 2022-02-23
On January 12, 2022, a research paper titled "Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy" was published online in Science Advances by Wang Yi and Chen Zhong from Zhejiang University of Traditional Chinese Medicine.
-
New developments in epilepsy drugs: eslicarbazepine's first imitation approved soon
Time of Update: 2021-11-04
In China, the original eslicarbazepine acetate has not been approved for marketing, but the drug has been included in the "Second Batch of Encouraging Generic Drugs List" published on the National Health Commission website in March 2021 .
-
New drug for epilepsy! EU CHMP recommends approval of Xcopri (cenobamate): complementary treatment of adult eclampsia epilepsy!
Time of Update: 2021-03-02
recently, the company announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued an active review recommending the approval of Xcopri (cenobamate), an anti-epileptic drug (AED) for adult patients with epilepsy who have previously been treated with at least two anti-epileptic drugs (ASM) but have not been adequately controlled, to assist in the treatment of developed seizures (accompanied or not accompanied by systemic seizures).
-
New chinese epilepsy drug! Ukip Vimpat is approved for use in adolescent and adult epilepsy patients
Time of Update: 2021-02-17
In the European Union, Vimpat was first approved in September 2008 as an ancillary drug for the treatment of partial seizure epilepsy (accompanied or not accompanied by secondary comprehensive seizure epilepsy) in children, adolescents and adults aged 4 years and older.
-
Responsitable pediatric epilepsy new drug! Aquestive's drug Sympazan is listed in the U.S. as the first chlorpyrine mouth:
Time of Update: 2021-02-17
The approval makes Sympazan the first and only oral membrane agent approved by the FDA to treat LGS-related seizures.
We believe Sympazan oral membranes will be an important treatment that is popular with LGS patient groups and caregivers.
-
Rare new drug for children with epilepsy! Fintepla is approved by the European Union to treat patients with ≥-year-old Dravet syndrome!
Time of Update: 2021-01-03
results showed that fintepla significantly reduced the frequency of monthly convulsive seizures (convulsive seizures, CS) compared to placebos in patients who took one or more anti-epileptic drugs that did not adequately control seizures.
-
New drugs for children with epilepsy! Vesei Fycompa (Wexter ®, Villenem Panai) has been approved
Time of Update: 2020-11-28
November 18, 2020 // -- Eisai (Eisai) recently announced that the European Commission (EC) has approved the anti-epileptic drug Fycompa (Wycombe ®, common name: perampanel, erampanae) to expand the ap
-
Chinese epilepsy patients gospel! A new generation of anti-epileptic drug ® (Fycompa, ®) 2 supplementary applications were accepted!
Time of Update: 2020-11-01
In addition, Fycompa has been approved by more than 65 countries worldwide, including the United States, Japan and other European and Asian countries, as an ancillary therapy for the treatment of primary full-range PGTC seizures in patients with epilepsy aged 12 years and older.
-
Rare new drug for children with epilepsy! Fintepla (fenfluoramine oral solution) is recommended by the EU CHMP for the treatment of Dravet syndrome!
Time of Update: 2020-11-01
recently, the company announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued an active review recommending approval of Fenfluramine oral solution as an additional (add-on) therapy for other anti-epileptic drugs for patients ≥2 years of age with Dravet syndrome.
-
New drug for epilepsy! Weisai Fycompa (Wexter ®, Villenem Panai) by the European Union CHMP
Time of Update: 2020-10-06
As an AMPA-like antagonist, Fycompa reduces excessive excitation of neurons associated with seizures by targeting the activity of the AMPA-Glutamate after synapses; To date, Fycompa has been approved by more than 70 countries worldwide, including Japan, the United States, China, and other countries in Europe and Asia, as an ancillary therapy for the treatment of partial seizures (POS, with or without secondary systemic seizures) in patients aged 12 and over.